Currently, tumor treatments are characterized by intelligence, diversity and personalization,
but the therapeutic reagents used are often limited in clinical efficacy due to problems with …

Simple Summary Although a notable evolution was recorded in the field of cancer, both in
terms of therapeutic options and diagnostic tools, with nanotechnology contributing …

Radiation therapy (RT), including external beam radiotherapy (EBRT) and internal
radioisotope therapy (RIT), has been an indispensable strategy for cancer therapy in clinical …

Targeted radionuclide therapy has become increasingly prominent as a nuclear medicine
subspecialty. For many decades, treatment with radionuclides has been mainly restricted to …

Cutaneous melanoma arises from proliferating melanocytes, cells specialized in the
production of melanin. This property means melanin can be considered as a target for …

In line with the ongoing phase I trial (NCT03784625) dedicated to melanoma targeted
radionuclide therapy (TRT), we explore the interplay between immune system and the …

Melanin is one of the representative biomarkers of malignant melanoma and a potential
target for diagnosis and therapy. With advancements in chemistry and radiolabeling …

Melanoma represents the most aggressive form of skin cancer, and its incidence continues
to rise worldwide. 18 F–FDG PET imaging has transformed diagnostic nuclear medicine and …

Nearly 100,000 individuals are expected to be diagnosed with melanoma in the United
States in 2022. Treatment options for late-stage metastatic disease up until the 2010s were …

Background Benzamide-based radioligands targeting melanin were first developed for
imaging melanoma and then for therapeutic purpose with targeted radionuclide therapy …